Sign in to view content

Masked Safety Data from ZETA-1, an Ongoing 24-Week Phase 2 Clinical Trial of APX3330, an Oral Therapeutic Being Developed for the Treatment of Diabetic Retinopathy

Michael J Allingham, MD, PhD

Video
Published 2022

Related

ASRS Presidents' Retina Young Investigators Award, Advancing Insights Into Diabetic Eye Disease, Rishi P. Singh, MD
Rishi P. Singh, MD
Annual Meeting Talks
2018
Presumed Silicone Oil Droplets
Rahul N. Khurana, MD, FASRS
Updates from the Field
2017
Vision Threatening Complications in Patients With Diabetic Macular Edema: A Post Hoc Analysis of the VISTA and VIVID Trials
Diana V Do, MD, FASRS
Annual Meeting Talks
2019

Category: Diabetic Retinopathy

See more